HUTCHMED (China) Limited

Total oncology revenue was $286 million in 2025, including $71 million of R&D-related upfront and milestone revenues. Net income was $457 million, mainly due to a $416 million SHPL divestment gain; excluding that one-time gain, management said core operations remained profitable. R&D expenses were $148 million, lower than 2024 because multiple late-stage trials were nearing completion and capital was shifting toward early-stage ATTC assets. Cash ended at about $1.4 billion. For 2026, oncology revenue is guided to $330 million to $450 million, with growth expected from China commercial products, new indications, and continued FRUZAQLA expansion; management also said the midpoint implies about 36% growth versus 2025 performance.

Johnny Cheng emphasized that HUTCHMED is moving into a new phase built around both commercial products and the ATTC platform. He said the company is using its $1.4 billion cash balance to accelerate global ATTC development, explore in-licensing and M&A, and pursue business development with multinational partners. His tone was upbeat but measured, repeatedly stressing that the company wants to grow while remaining sustainably profitable.

Lorenso Chiu highlighted 2025 oncology revenue of $286 million, including $71 million of R&D-related upfront and milestone revenue, and net income of $457 million, largely from the $416 million SHPL divestment gain. He noted R&D expense of $148 million and said lower spending reflected late-stage trials nearing completion and a shift toward early-stage ATTC programs. Looking ahead, he guided 2026 oncology revenue to $330 million to $450 million and said the range reflects China product growth, new indications such as RCC, and continued FRUZAQLA expansion.

Analysts focused on the wide 2026 revenue range, the delay in SAFFRON readout timing, ATTC development details, the impact of Medicare Part D changes, and the company’s partnership plans. Management said the revenue guidance assumes continued recovery in China, strong FRUZAQLA expansion across more countries, and new indication contributions, while also leaving room for potential licensing income. On SAFFRON, they said the readout is expected around mid-2026, and on ATTC they said A251 is enrolling HER2-expressing solid tumor patients rather than being limited to post-HER2 patients. Management also said U.S. Medicare Part D impacts were already reflected, the commercial team has been reset after earlier setbacks, and no fixed M&A or licensing targets are set.